Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
04/2003
04/10/2003WO2003029265A1 Inosinie/l-arginine salt and use thereof
04/10/2003WO2003029264A2 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
04/10/2003WO2003029254A1 Process for preparation of tricyclic compounds
04/10/2003WO2003029248A1 N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds
04/10/2003WO2003029247A1 N-heterocyclyl hydrazides as neurotrophic agents
04/10/2003WO2003029233A1 New sulfonamide derivatives as d3-receptor agonists
04/10/2003WO2003029232A1 Phenyl-piperazine derivatives as serotonin reuptake inhibitors
04/10/2003WO2003029224A1 6-membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade
04/10/2003WO2003029221A1 Tetrahydroisochinolines, their production and the use thereof as analgesics
04/10/2003WO2003029218A1 Novel nitrogenous compound and use thereof
04/10/2003WO2003029217A2 Pyridinic sulfonamide derivatives, method of production and use thereof
04/10/2003WO2003029216A1 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
04/10/2003WO2003029212A1 Indole derivatives as cox ii inhibitors
04/10/2003WO2003029209A2 Chemical compounds
04/10/2003WO2003029200A2 Compounds useful as reversible inhibitors of cysteine proteases
04/10/2003WO2003029187A1 Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them
04/10/2003WO2003029185A1 Novel compounds
04/10/2003WO2003028840A2 Combined compositions and methods for tumor vasculature coagulation and treatment
04/10/2003WO2003028764A1 Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
04/10/2003WO2003028759A1 Rsv gene expression vaccine
04/10/2003WO2003028757A1 Novel method of inducing antigen-specific t cells
04/10/2003WO2003028754A1 Method for treating hepatitis c virus infection in treatment failure patients
04/10/2003WO2003028749A1 Matrix metalloprotease inhibitor
04/10/2003WO2003028744A1 Process for producing collagen production enhancers and use thereof
04/10/2003WO2003028737A1 Anti-viral agents and in-vitro method for the identification of candidates able to inhibit binding of polymerase to epsilon
04/10/2003WO2003028736A2 Pharmaceutical preparations comprising alkyl phosphocholine compounds in liposomes which may be sterile-filtered or heat-sterilised
04/10/2003WO2003028732A1 Receptor antagonist
04/10/2003WO2003028730A2 Pharmaceutical combinations of pde-v inhibitors and other agents
04/10/2003WO2003028729A2 Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
04/10/2003WO2003028727A1 3-`hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors
04/10/2003WO2003028726A1 Quinoline derivatives as neuropeptide y antagonists
04/10/2003WO2003028723A1 Pharmaceutical compositions for percutaneous absorption containing fused imidazopyridine derivatives
04/10/2003WO2003028722A1 Treatment of hepatitis b virus infection with human monoclonal antibodies
04/10/2003WO2003028721A2 Substituted benzimidazole compounds and their use for the treatment of cancer
04/10/2003WO2003028720A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
04/10/2003WO2003028701A2 Liposomes containing (ether)lysolecithins
04/10/2003WO2003028697A2 Liposome loading with metal ions
04/10/2003WO2003028692A2 Acne treatment using oleanolic acid
04/10/2003WO2003028650A2 Benzimidazolidinone derivatives as muscarinic agents
04/10/2003WO2003028642A2 Methods of inhibiting metastases
04/10/2003WO2003028641A2 Mch receptor antagonists
04/10/2003WO2003028634A2 Method of treatment using ligand-immunogen conjugates
04/10/2003WO2003028630A2 Methods and compositions for modulating interleukin-21 receptor activity
04/10/2003WO2003028590A1 Rational drug therapy device and methods
04/10/2003WO2003028537A2 Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
04/10/2003WO2003028536A2 Methods for diagnosing and treating heart disease
04/10/2003WO2003014326A3 Isolation and mobilization of stem cells expressing vegfr-1
04/10/2003WO2003013564A3 An herbal composition for the treatment and remedy of bronchial respiratory difficulties
04/10/2003WO2003011300B1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
04/10/2003WO2003006607A9 Inhibition of apoptosis process and improvement of cell performance
04/10/2003WO2003002598A3 Peptides for use as translocation factors
04/10/2003WO2003002092A3 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
04/10/2003WO2003000709A9 Sialic acid derivatives for use as siglec inhibitors
04/10/2003WO2003000118A3 Method for enhancing the effectiveness of cancer therapies
04/10/2003WO2003000114A3 Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
04/10/2003WO2002102978A3 Human growth hormone antagonists
04/10/2003WO2002102768A3 Regulation of neuronal function through metabotropic glutamate receptor signaling pathways
04/10/2003WO2002100348A8 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
04/10/2003WO2002096467A3 Pharmaceutical use for secreted bacterial effector proteins
04/10/2003WO2002094830A8 Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists
04/10/2003WO2002094203A3 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
04/10/2003WO2002092622A3 Dipeptide derivatives having a n-terminal 2-thioacyl group as vasopeptidase inhibitors
04/10/2003WO2002083108A3 Compositions containing cgmp pde inhibitors and local anaesthetic agents for nasal application
04/10/2003WO2002080982A9 Nucleic acid mucosal immunization
04/10/2003WO2002078639A3 A method of treating proliferative diseases using eg5 inhibitors
04/10/2003WO2002074238A3 Water soluble and palatable complexes
04/10/2003WO2002071827A3 Retinoid x receptor modulators
04/10/2003WO2002070540A3 Peptide deformylase inhibitors
04/10/2003WO2002070070A3 Compositions having improved bioavailability of eletriptan
04/10/2003WO2002065988A3 Terminally-branched polymeric linkers and polymeric conjugates containing the same
04/10/2003WO2002059083A3 Novel compounds
04/10/2003WO2002057460A3 Polynucleotides encoding human phosphatases
04/10/2003WO2002055688A3 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
04/10/2003WO2002055152A3 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands
04/10/2003WO2002050122A3 Means for the diagnosis and therapy of ctcl
04/10/2003WO2002036135A3 Compositions for antitumour treatment containing ecteinascidin 743
04/10/2003WO2002034241A3 Compounds comprising a phytosterol and/or phytostanol moiety and ascorbis acid and use thereof as weight regulating agents
04/10/2003WO2002008396A3 Human proteases
04/10/2003WO2001087295A8 Methods for decreasing cell proliferation based on (3r, 4r)-δ8-tetrahydrocannabinol-11-oic acids
04/10/2003US20030070184 Ligands for discoidin domain receptor tyrosine kinases and complexes thereof
04/10/2003US20030069434 Antiestrogenic properties or tissue-selective estrogenic properties
04/10/2003US20030069430 Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects
04/10/2003US20030069429 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress
04/10/2003US20030069428 Pharmaceutically active isoindoline derivatives
04/10/2003US20030069419 Method for producing 1-substituted-1,2,3- triazole derivative
04/10/2003US20030069416 Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives
04/10/2003US20030069405 70 human secreted proteins
04/10/2003US20030069315 New use for 1,3-propanediol derivatives
04/10/2003US20030069312 Nitromethyl ketones, process for preparing them and compositions containing them
04/10/2003US20030069311 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
04/10/2003US20030069298 Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof
04/10/2003US20030069297 4-aryl substituted indolinones
04/10/2003US20030069296 Central nervous system disorders
04/10/2003US20030069294 Alpha-substituted carboxylic acid derivatives
04/10/2003US20030069292 Central nervous system disorders; anticonvulsants
04/10/2003US20030069290 Substituted-heteroaryl-7-aza[2.2.1] bycycloheptanes for the treatment of desease
04/10/2003US20030069289 Alzheimer*s disease
04/10/2003US20030069287 Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors
04/10/2003US20030069284 Anticancer agent
04/10/2003US20030069279 Antimicrobial agent
1 ... 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 ... 1564